Matinas BioPharma Holdings, Inc.
(NYSE Amex Equities : MTNB)

( )
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Like Small Cap Stocks < $20?
You should, we just banked a 30% winner in 2 days!
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
BIIBBiogen, Inc.
-0.22%291.601.4%$589.25m
AMGNAmgen, Inc.
0.13%234.311.3%$503.84m
GILDGilead Sciences, Inc.
0.25%67.321.0%$363.83m
REGNRegeneron Pharmaceuticals, Inc.
0.40%375.032.6%$303.74m
VRTXVertex Pharmaceuticals, Inc.
-0.29%219.361.9%$272.22m
ILMNIllumina, Inc.
-0.23%319.823.5%$231.34m
CLVSClovis Oncology, Inc.
7.51%12.6014.7%$223.41m
ARWRArrowhead Pharmaceuticals, Inc.
-2.16%66.7511.4%$203.34m
ALXNAlexion Pharmaceuticals, Inc.
1.81%111.482.0%$198.56m
EXASEXACT Sciences Corp.
0.06%85.2224.0%$163.42m
AAgilent Technologies, Inc.
0.79%84.081.6%$160.33m
BLUEbluebird bio, Inc.
-2.05%85.1914.2%$136.94m
GBTGlobal Blood Therapeutics, Inc.
-3.82%75.466.0%$136.67m
BOLDAudentes Therapeutics, Inc.
-0.05%59.411.4%$134.19m
SGENSeattle Genetics, Inc.
-0.05%111.286.1%$128.47m

Company Profile

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company, which focuses on enabling the delivery of life-changing medicines using its LNC platform technology. The company's proprietary, disruptive technology utilizes lipid nano-crystals which can encapsulate small molecule drugs, oligonucleotides, vaccines, peptides, proteins, and other medicines potentially making them safer, more tolerable, less toxic, and orally bioavailable. Its anti-fungal product candidate, MAT2203, delivers broad-spectrum fungicidal agent, amphotericin B; and is being developed to prevent invasive fungal infections in patients with acute lymphoblastic leukemia. The company was founded in May 2013 and is headquartered in Bedminster, NJ.